MX385604B - Composiciones y metodos para diagnosis y tratamiento de anemia - Google Patents

Composiciones y metodos para diagnosis y tratamiento de anemia

Info

Publication number
MX385604B
MX385604B MX2020004767A MX2020004767A MX385604B MX 385604 B MX385604 B MX 385604B MX 2020004767 A MX2020004767 A MX 2020004767A MX 2020004767 A MX2020004767 A MX 2020004767A MX 385604 B MX385604 B MX 385604B
Authority
MX
Mexico
Prior art keywords
methods
compositions
anemia
treatment
conditions
Prior art date
Application number
MX2020004767A
Other languages
English (en)
Other versions
MX2020004767A (es
Inventor
Mark Baird
Stephanie Kay Venn-Watson
Original Assignee
The United States 0F America As Represented By The Secretary 0F The Navy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States 0F America As Represented By The Secretary 0F The Navy filed Critical The United States 0F America As Represented By The Secretary 0F The Navy
Publication of MX2020004767A publication Critical patent/MX2020004767A/es
Publication of MX385604B publication Critical patent/MX385604B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Se proporcionan composiciones que incluyen un ácido graso, tal como un ácido graso de cadena impar o un ácido graso de cadena par muy larga, y sales y derivados de los mismos, y métodos para el tratamiento y profilaxis de condiciones relacionadas a condiciones anémicas, que incluyen composiciones y métodos para tratar condiciones anémicas tal como anemia hemolítica y anemia de enfermedad crónica, y otras condiciones relacionadas.
MX2020004767A 2016-12-29 2018-01-08 Composiciones y metodos para diagnosis y tratamiento de anemia MX385604B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15/393,771 US10238618B2 (en) 2016-12-29 2016-12-29 Compositions and methods for diagnosis and treatment of anemia

Publications (2)

Publication Number Publication Date
MX2020004767A MX2020004767A (es) 2021-08-26
MX385604B true MX385604B (es) 2025-03-18

Family

ID=61022302

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004767A MX385604B (es) 2016-12-29 2018-01-08 Composiciones y metodos para diagnosis y tratamiento de anemia
MX2018000013A MX378434B (es) 2016-12-29 2018-01-08 Composiciones y métodos para diagnosis y tratamiento de anemia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018000013A MX378434B (es) 2016-12-29 2018-01-08 Composiciones y métodos para diagnosis y tratamiento de anemia.

Country Status (7)

Country Link
US (3) US10238618B2 (es)
EP (2) EP3562481B1 (es)
JP (1) JP7037367B2 (es)
CA (1) CA3039591A1 (es)
ES (1) ES2899635T3 (es)
MX (2) MX385604B (es)
WO (1) WO2018122407A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9561206B2 (en) * 2015-01-07 2017-02-07 The United States Of America, As Represented By The Secretary Of The Navy Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome
US10307388B2 (en) * 2016-12-29 2019-06-04 The United States Of America As Represented By The Secretary Of The Navy Compositions and methods for diagnosis and treatment of inflammation
US10792266B2 (en) 2017-10-23 2020-10-06 Epitracker, Inc. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
JP2021525249A (ja) 2018-05-23 2021-09-24 エピトラッカー インコーポレイテッドＥｐｉｔｒａｃｋｅｒ， Ｉｎｃ． 加齢及び長期性の質に関連する状態の診断及び治療のための組成物及び方法
EP3908374A4 (en) 2019-01-09 2022-12-28 Epitracker, Inc. COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES
WO2020154173A1 (en) * 2019-01-23 2020-07-30 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
WO2022005879A1 (en) * 2020-07-01 2022-01-06 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating bone marrow failure syndromes and compositions for use in the same
US12370166B2 (en) 2021-11-03 2025-07-29 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity
CN116473951A (zh) * 2022-06-03 2023-07-25 中国科学院生物物理研究所 用于卵巢功能障碍性疾病的活性分子及其衍生物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR79620E (fr) 1958-05-29 1962-12-28 Hercules Powder Co Ltd Polymérisation de composés époxydés
DE2615061A1 (de) 1976-04-05 1977-10-06 Wolfgang Dr Med Wagner Injektionsverfahren und -vorrichtungen
US4252159A (en) 1979-04-02 1981-02-24 Maki Eugene B Dosage device
DE3501534A1 (de) 1984-09-22 1986-05-15 Walter Ing.(grad.) 7758 Meersburg Holzer Verfahren und vorrichtung zum dosieren von insulin oder aehnlichen langzeitmedikamenten
EP0317705B1 (de) 1987-11-25 1992-09-30 Siemens Aktiengesellschaft Dosiergerät zum gesteuerten Injizieren von Flüssigkeiten aus einem Vorratsbehälter in einen Organismus
EP0569618B1 (de) 1992-05-12 1997-01-02 Siemens-Elema AB Dosiergerät zur gesteuerten Abgabe einer Flüssigkeit
US7651845B2 (en) 2004-05-13 2010-01-26 The Regents Of The University Of California Method and apparatus for glucose control and insulin dosing for diabetics
EP3300727A1 (en) * 2004-07-02 2018-04-04 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
US8251904B2 (en) 2005-06-09 2012-08-28 Roche Diagnostics Operations, Inc. Device and method for insulin dosing
US20070203235A1 (en) * 2006-02-28 2007-08-30 Rosales Francisco J Method for preventing or treating anemia
NZ555163A (en) * 2007-05-14 2010-05-28 Fonterra Co Operative Group Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
DE102007055636A1 (de) 2007-11-21 2009-05-28 Robert Bosch Gmbh Medikamenten-Dosiervorrichtung zum Verabreichen eines flüssigen Medikaments
US20120072236A1 (en) 2010-08-06 2012-03-22 Benjamin Atkin Insulin pen data recording and transmission device
JP6084932B2 (ja) 2011-02-09 2017-02-22 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 夜間基礎投薬デバイス
US9561206B2 (en) * 2015-01-07 2017-02-07 The United States Of America, As Represented By The Secretary Of The Navy Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome
US10307388B2 (en) 2016-12-29 2019-06-04 The United States Of America As Represented By The Secretary Of The Navy Compositions and methods for diagnosis and treatment of inflammation

Also Published As

Publication number Publication date
US20200022939A1 (en) 2020-01-23
CA3039591A1 (en) 2018-07-05
MX2018000013A (es) 2018-11-09
EP3922244A1 (en) 2021-12-15
JP2018135318A (ja) 2018-08-30
US20190201362A1 (en) 2019-07-04
US10238618B2 (en) 2019-03-26
WO2018122407A1 (en) 2018-07-05
US20180185315A1 (en) 2018-07-05
JP7037367B2 (ja) 2022-03-16
MX2020004767A (es) 2021-08-26
EP3562481A1 (en) 2019-11-06
ES2899635T3 (es) 2022-03-14
EP3562481B1 (en) 2021-08-25
MX378434B (es) 2025-03-10

Similar Documents

Publication Publication Date Title
MX385604B (es) Composiciones y metodos para diagnosis y tratamiento de anemia
SA520411125B1 (ar) Nlrp مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط
MX380092B (es) Tratamiento de la osteoartritis.
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
SG11201901061QA (en) Heterocyclic compound
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201491968A1 (ru) Производные имидазотиадиазола и имидазопиридазина в качестве ингибиторов активируемых протеазой рецепторов 4 (par4) для лечения агрегации тромбоцитов
CL2015002334A1 (es) Modificador del sabor dulce
MY197698A (en) Oxysterols and methods of use thereof
CL2017001650A1 (es) Derivados de 5-[(piperazina-1-yl)-3-oxo-propilo]-imidazolidina-2,4-dionan como inhibidores adamts para el tratamiento oesteoartritis.
EA201791182A1 (ru) Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
BR112016021648A2 (pt) novos compostos
MX2016012835A (es) Composiciones y metodos para tratar las espinillas.
MX391440B (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
MX382175B (es) Composiciones de profármaco de monometilfumarato
PH12017500007A1 (en) Quinolizinone derivatives as p13k inhibitors
MX384724B (es) Regímenes de dosificación de melflufen para cáncer.
EA033342B1 (ru) Пирролидинкарбоксамидо производные и способы их получения и их применение
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
PH12016502568B1 (en) Novel heterocyclic compound
PH12017501735A1 (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same